Vincere Biosciences is a biotechnology company developing novel therapeutics for neurodegenerative diseases, with a primary focus on Parkinson's disease and related disorders. The company's name reflects its mission to "conquer" neurodegenerative disease through innovative science targeting protein homeostasis and genetic risk factors.
| Attribute |
Details |
| Founded |
~2021 |
| Headquarters |
USA |
| Focus |
Parkinson's disease, Neurodegeneration |
| Status |
Private |
| Stage |
Preclinical/Discovery |
Vincere Biosciences focuses on:
- Disease-modifying therapies for PD — Moving beyond symptomatic treatment to target underlying pathology
- Targeting genetic risk factors — Including LRRK2, GBA1, and other PD-associated genes
- Protein homeostasis pathways — Enhancing autophagy and lysosomal function
The company is developing:
- Small molecule inhibitors — Brain-penetrant compounds targeting key neurodegenerative pathways
- Novel target validation — Discovering and validating new therapeutic targets
- Biomarker-driven development — Using biomarkers for patient selection and target engagement
| Drug |
Mechanism |
Phase |
Indication |
| VB-101 |
LRRK2 inhibitor |
Preclinical |
Parkinson's disease |
| VB-102 |
Autophagy enhancer |
Discovery |
Parkinson's disease |
| VB-103 |
GBA1 modulator |
Discovery |
Parkinson's disease |
- Mechanism: Small molecule LRRK2 kinase inhibitor
- Target: Mutant LRRK2 (G2019S) and wild-type LRRK2
- Phase: Preclinical
- Rationale: LRRK2 mutations are the most common genetic risk factor for familial PD
- Mechanism: Enhances autophagy flux
- Target: Lysosomal function, protein clearance
- Phase: Discovery
- Rationale: Impaired autophagy is a hallmark of neurodegenerative diseases
LRRK2 (leucine-rich repeat kinase 2) is an attractive target because:
- Genetic Validation — LRRK2 mutations cause familial Parkinson's disease
- Mechanism — Hyperactive LRRK2 impairs autophagy and lysosomal function
- Prevalence — G2019S mutation found in 5-6% of PD patients
- Therapeutic Window — Partial inhibition may provide benefit without toxicity
GBA1 (glucocerebrosidase) is another key target:
- Genetic Risk — GBA1 mutations increase PD risk 5-10x
- Mechanism — Loss of GBA1 function leads to alpha-synuclein accumulation
- Patient Population — Significant portion of PD patients have GBA1 variants
- Combination Potential — May synergize with LRRK2 inhibition
¶ Competitive Landscape
| Company |
Drug |
Mechanism |
Phase |
| Denali/Biogen |
DNL151 (BIIB122) |
LRRK2 inhibitor |
Phase 2b |
| Vanqua Bio |
VQVN-0001 |
LRRK2 inhibitor |
Preclinical |
| Roche |
-- |
LRRK2 inhibitor |
Preclinical |
| Merck |
-- |
LRRK2 inhibitor |
Phase 1 |